11th Annual Western AF Symposium Agenda

Each year great advancements in Atrial fibrillation research help to further the medical field and improve our patient’s treatment and quality of life. Enjoy discussion panels and listen to some of the top AF leaders and physicians at the 11th annual WAF Symposium. View the 2018 AF Symposium schedule for the 23-24th of February.

Download Full WAF 2018 Agenda Here


Register Now

Friday, February 23, 2018

6:45 am
Registration & Breakfast
7:15 am
Nassir Marrouche, MD
Kevin Campbell, MD; John Mandrola, MD

Session 1:

Chairs: Melvin Scheinman, MD; Fred Han, MD 

7:30 amIs AF ablation safer than AAD? A systematic review
John P. DiMarco, MD, PhD
7:45 amInteraction between hypercoagulability and atrial fibrillation
Ulrich Schotten, MD, PhD
8:00 amClinical outcomes of AF mapping and rotor guided ablation
David Wilber, MD
8:15 amLAA closure: Long-term follow-up data
Rahul N. Doshi, MD
8:30 amPredisposition gene discovery in Utah: Atrial fibrillation and fibrosis
Lisa Cannon-Albright, PhD
8:45 amQ&A

Session 2:

Chairs: David Wilber, MD; Roger Freedman, MD

9:00 amIt is all about lesion delivery: Is electroporation the future of AF ablation?
Pierre Jais, MD
9:15 amAtrial MR imaging: How to improve resolution?
Dana C. Peters, PhD
9:30 amLAA closure devices: Benefit beyond stroke prevention?
Dhanunjaya Lakkireddy, MD
9:45 amIs AF a marker or a risk for stroke?
Nazem Akoum, MD, MS
10:00 amQ&A
10:15 amBreak

Session 3:

Chairs: Jonathan Piccini, MD; Melvin Scheinman, MD

10:30 am
Is AF ablation a first-line therapy in 2018?
Eric Prystowsky, MD
10:45 am
CABANA: What to expect?
Douglas Packer, MD
11:00 am
Is atrial fibrosis reversible: Insights from experimental evidence
Stanley Nattel, MD
11:15 am
QoL post AF ablation: the CAPTAF trial
Carina Blomström-Lundqvist, MD, PhD
11:30 am
11:45 am

Session 4:

Chairs: Michael Cutler, DO, PhD; Fred Han, MD 

12:30 pm
Cryo-balloon for AF: Long-term results
Bradley Knight, MD
12:45 pm
Is it AF or the myopathy? Lessons from MR imaging
Saman Nazarian, MD, PhD
1:00 pm
Atrial fibrosis modeling: Clinical implications
Natalia Trayanova, PhD
1:15 pm
Mortality benefit post AF ablation: The CASTLE-AF trial
Johannes Brachmann, MD
1:30 pmQ&A

Session 5:

Chairs: Jonathan Piccini, MD; Roger Freedman, MD

1:45 pm
Do we still need to monitor for asymptomatic AF after ablation?
Suneet Mittal, MD
2:00 pm
Rotational activity and atrial fibrosis: How DECAAF II might help?
Christian Sohns, MD
2:15 pm
Post-ablation blanking period: 4, 8, 12 or zero weeks?
David Callans, MD
2:30 pmCatheterized fiber-optics confocal microscopy for mapping of atrial fibrosis
Frank B. Sachse, PhD
2:45 pmQ&A
3:00 pmBreak

Session 6:

Chairs: David Callans, MD; Saman Nazarian, MD, PhD

3:15 pm
Targeting rotational activity during re-do procedures
Sanjiv M. Narayan, MD, PhD
3:30 pm
CASTLE-AF: What we learned beyond the primary endpoint
Nassir Marrouche, MD
3:45 pm
Treatment of esophageal injury post AF ablation: A GI perspective
Deborah Fisher, MD, MHS
4:00 pm
AF in heart failure patients: Lessons from SCD-HeFT
Jeanne Poole, MD
4:15 pm

Session 7:

Chairs: Frank B. Sachse, PhD; Suneet Mittal, MD

4:30 pm Esophageal protection during AF ablation
Moussa C. Mansour, MD
4:45 pmWhen to anticoagulate AF patients with CHA2DS2-VASc <2?
Andrea M. Russo, MD
5:00 pmRisk factors for AF in women
Christine Albert, MD, MPH
5:15 pmQ&A
5:25 pmBreak

Session 8:

Moderators: Walid Saliba, MD; Darryl S. Wells, MD  

5:35 pmRoundtable: How, when and why to monitor for AF—Examples from practice
Andres Bochoeyer, MD; Bengt Herweg, MD; Nischala Nannapaneni, MD; Kamran Rizvi, MD; T. Scott Wall, MD; Bassam Wanna, MD
6:30 pm

Saturday, February 24, 2018

6:45 am
Registration & Breakfast
Exhibits open

Session 9:

Chairs: John Mandrola, MD; Alexies Ramirez, MD 

7:15 amReal-world impact of NOACs: Neurologist perspective
Scott Brehaut, MD
7:30 am ESC AF guidelines update
Gerhard Hindricks, MD, PhD
7:45 amHow much AF is too much? (Especially with wearables everywhere…)
Mintu Turakhia, MD
8:00 amDebate: DOACs should be given for at least 6 weeks post-LAA implant
Pro: Jonathan Lowy, MD
Con: Julian Chun, MD
8:15 amQ&A

Session 10:

Chairs: Fred Han, MD; Julian Chun, MD 

8:30 amContemporary real-world and registry data of NOACs: Is Coumadin dead?
Jonathan Hsu, MD, MAS
8:45 amLow-voltage zone vs MR detected fibrosis: A comparison
Takanorai Yamaguchi, MD
9:00 amWhy are we struggling to agree on an ideal mapping system for AF?
Olaf Döessel, PhD
9:15 amAblation of AF: 10 years of follow-up
Andrea Natale, MD
9:30 amQ&A
9:45 amBreak

Session 11:

Chairs: Prash Sanders, MBBS, PhD; Thomas J. McGarry, MD, PhD 

10:00 amAF & OSA: Chicken and the egg
Thomas F. Deering, MD, MBA
10:15 amCardiac fibrosis and treatment outcome: Lessons from CAMERA-MRI
Jonathan M. Kalman, MBBS, PhD
10:30 amA novel AF risk scoring model using MRI
Brent D. Wilson, MD, PhD
10:45 amHigh-power, short-duration lesions during AF ablation: Lessons from MRI
Mihail G. Chelu, MD, PhD
11:00 amMR pulmonary vein scans in AF patients: More to it than just fibrosis
Christopher J. McGann, MD
11:15 amQ&A
11:30 amLunch

Session 12:

Chairs: Thomas Deneke, MD; Vikas Sharma, MD 

12:30 pmApproaches to ablate persistent AF in 2018: Why too many?
Gregory Michaud, MD
12:45 pmHow to modify lifestyle and educate the AF patient?
Prash Sanders, MBBS, PhD
1:00 pmRole of atrial fibrosis during surgical AF ablation
Ralph J. Damiano, Jr., MD
1:15 pmHow to best monitor treatment with NOACs?
Elaine M. Hylek, MD, MPH
1:30 pmQ&A

Session 13:

Chairs: Atul Verma, MD; Stephen Rechenmacher, MD 

1:45 pmReal-time MRI cryo-balloon guided ablation
Evgueni G. Kholmovski, PhD
2:00 pmRadiofrequency balloon systems
Amin Al-Ahmad, MD
2:15 pmReal-time MRI for cardiac ablation
Philipp Sommer, MD
2:30 pmIs transmural lesion an important endpoint during AF ablation? Show me the data!
David Haines, MD
2:45 pmQ&A
3:00 pmBreak

Session 14:

Chairs:Christian Mahnkopf, MD; David Haines, MD 

3:15 pmPatient-reported outcomes in AF
Benjamin A. Steinberg, MD, MHS
3:30 pmOff-label treatment of AF
Kimberly A. Selzman, MD, MPH
3:45 pmImportance of durable PVI for persistent AF
Atul Verma, MD
4:00 pmQ&A

Session 15:

Chairs: Philip Sommer, MD; David Haines, MD 

4:15 pmTreatment of AF: Heart failure specialist’s perspective
Heribert Schunkert, MD
4:30 pm Lessons learned from acute and chronic ablation lesion visualization using MRI
Ravi Ranjan, MD, PhD
4:45 pmHow early should we ablate AF? Temporal and structural criteria
Oussama Wazni, MD
5:00 pmQ&A

Session 16:

Moderators: Kevin Campbell, MD; John Mandrola, MD 

5:15 pm#ASKWAF:
Mihail G. Chelu, MD, PhD; John D. Day, MD; Christian Mahnkopf, MD; Debbe McCall, MBA; Jonathan Piccini, MD; Mellanie True Hills; Oussama Wazni, MD
6:30 pm Adjourn

*Agenda is subject to change

Download Full WAF 2018 Agenda Here